MyFinsight
Home
Blog
About
Net income (loss)
$51,291K
(472.02%↑ Y/Y)
Deferred income taxes
$15,173K
(2.69%↑ Y/Y)
Share-based compensation
expense
$3,236K
(-67.03%↓ Y/Y)
Accrued research and
development costs
$1,124K
(142.19%↑ Y/Y)
Depreciation and
amortization
$457K
(-51.69%↓ Y/Y)
Non-cash lease expense
$453K
(-45.22%↓ Y/Y)
Non-cash interest
expense
$389K
(-53.25%↓ Y/Y)
Other assets
-$17K
(94.01%↑ Y/Y)
Net cash provided by
operating activities
$58,276K
(1092.71%↑ Y/Y)
Effect of exchange rate
changes on cash and cash...
$77K
(111.77%↑ Y/Y)
Canceled cashflow
$13,864K
Net increase
(decrease) in cash and cash...
-$141,344K
(-3392.43%↓ Y/Y)
Canceled cashflow
$58,353K
Proceeds from employee
stock purchase plan
$303K
(222.34%↑ Y/Y)
Accounts receivable, net
$6,890K
(60.91%↑ Y/Y)
Accounts payable and
accrued expenses
-$4,614K
(-10.54%↓ Y/Y)
Prepaid expenses and
other current assets
$1,416K
(200.64%↑ Y/Y)
Operating lease
liabilities
-$635K
(45.07%↑ Y/Y)
Other liabilities
-$309K
(-108.01%↓ Y/Y)
Net cash provided by
(used in) financing...
-$199,697K
(-212543.62%↓ Y/Y)
Canceled cashflow
$303K
Repayment of 2026
convertible notes
$200,000K
Back
Back
Cash Flow
IRONWOOD PHARMACEUTICALS INC (IRWD)
IRONWOOD PHARMACEUTICALS INC (IRWD)
source: myfinsight.com